Chemours Analyst Price Targets - Benzinga

The Chemours Co

CCNYSE

Trade with Public

Trade with Public

$15.62

-0.26-1.64%

At close: Aug 28, 5:00 PM EST

$15.70

0.080.51%

After Hours: Aug 28, 5:40 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Chemours Analyst Price Targets

Wall Street analyst price targets and consensus rating for Chemours (CC).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

4Buy

3Hold

Consensus RatingOutperform# Analysts7Avg. Consensus PT$19Upside to Avg. PT+23.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	JP Morgan	Jeffrey Zekauskas	PT Cut	Neutral	$22→$15
Aug 13, 2026	BMO Capital	John McNulty	PT Cut	Outperform	$26→$18
Aug 10, 2026	UBS	Joshua Spector	Downgrade	Buy→Neutral	$29→$18
Aug 6, 2026	RBC Capital	Arun Viswanathan	PT Cut	Outperform	$26→$22
Aug 6, 2026	Truist Securities	Peter Osterland	PT Cut	Buy	$30→$24
Jul 1, 2026	Mizuho	John Roberts	PT Cut	Outperform	$30→$25
May 21, 2026	JP Morgan	Jeffrey Zekauskas	PT Raise	Neutral	$17→$22
May 11, 2026	Morgan Stanley	Vincent Andrews	PT Raise	Equal-Weight	$17→$21
May 11, 2026	RBC Capital	Arun Viswanathan	PT Raise	Outperform	$26→$29
May 8, 2026	UBS	Joshua Spector	PT Raise	Buy	$29→$30
Apr 28, 2026	Truist Securities	Peter Osterland	PT Raise	Buy	$27→$30
Apr 9, 2026	UBS	Joshua Spector	PT Raise	Buy	$23→$29
Apr 9, 2026	Truist Securities	Peter Osterland	PT Raise	Buy	$21→$27
Mar 5, 2026	Mizuho	John Roberts	PT Raise	Outperform	$17→$21
Feb 25, 2026	Goldman Sachs	Duffy Fischer	PT Raise	Neutral	$14→$18
Feb 23, 2026	UBS	Joshua Spector	PT Raise	Buy	$18→$23
Feb 23, 2026	BMO Capital	John McNulty	PT Cut	Outperform	$20→$19
Feb 23, 2026	JP Morgan	Jeffrey Zekauskas	PT Raise	Neutral	$13→$17
Feb 23, 2026	Morgan Stanley	Vincent Andrews	PT Raise	Equal-Weight	$15→$17
Jan 21, 2026	Truist Securities	Peter Osterland	PT Raise	Buy	$18→$21

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on Chemours, Lowers Price Target to $15

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $22 to $15.

Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on Chemours, Lowers Price Target to $18

BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $26 to $18.

Benzinga Newsdesk

Dick's Sporting To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

Analysts update ratings on top stocks. View all changes, including upgrades and downgrades, on analyst ratings page.

Avi Kapoor

PRO
UBS Downgrades Chemours to Neutral, Lowers Price Target to $18

UBS analyst Joshua Spector downgrades Chemours (NYSE:CC) from Buy to Neutral and lowers the price target from $29 to $18.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $22

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $26 to $22.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Chemours, Lowers Price Target to $24

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $30 to $24.

Benzinga Newsdesk